Loading..

Exact Sciences Corporation (EXAS) Report Analysis

Corporate Events

Positive

Exact Sciences Corporation(NasdaqCM:EXAS) added...

2022-06-24 00:00:00

Exact Sciences Corporation(NasdaqCM:EXAS) added to Russell 2500 Value Index

Positive

Exact Sciences Corporation(NasdaqCM:EXAS) added...

2022-06-24 00:00:00

Exact Sciences Corporation(NasdaqCM:EXAS) added to Russell 2500 Growth Index

Positive

Exact Sciences Corporation(NasdaqCM:EXAS) added...

2022-06-24 00:00:00

Exact Sciences Corporation(NasdaqCM:EXAS) added to Russell 2500 Index

Neutral

Declaration of Voting Results by Exact Sciences...

2022-06-10 16:24:00

On June 10, 2022, Exact Sciences Corporation announced that at its annual general meeting of shareholders held on June 9, 2022, the Company's ...

Neutral

Exact Sciences Corporation Presents at The 2022...

2022-05-29 01:15:00

Exact Sciences Corporation Presents at The 2022 ASCO Annual Meeting, Jun-03-2022 through Jun-07-2022. Venue: McCormick Place, Chicago, Illinoi...

Neutral

Nephron Research LLC, Nephron Liquid Biopsy Inn...

2022-05-27 10:00:00

Nephron Research LLC, Nephron Liquid Biopsy Innovation Symposium 2022, Jun 21, 2022.

Neutral

Exact Sciences Corporation Presents at William ...

2022-05-27 10:00:00

Exact Sciences Corporation Presents at William Blair’s 42nd Annual Growth Stock Conference 2022, Jun-06-2022 03:40 PM. Venue: Loews Chicago Ho...

Neutral

Exact Sciences Corporation Presents at 2022 Jef...

2022-05-27 10:00:00

Exact Sciences Corporation Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 01:00 PM. Venue: Marriott Marquis, New York Ci...

Neutral

Exact Sciences Corporation Presents at Goldman ...

2022-05-27 10:00:00

Exact Sciences Corporation Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-13-2022 03:20 PM. Venue: Terranea Resort, R...

Neutral

Exact Sciences Corporation Presents at Nephron ...

2022-05-27 10:00:00

Exact Sciences Corporation Presents at Nephron Liquid Biopsy Innovation Symposium 2022, Jun-21-2022 11:00 AM. Speakers: Jake Orville, General ...

Neutral

Exact Sciences Corporation Presents at BIO Inte...

2022-05-14 02:46:00

Exact Sciences Corporation Presents at BIO International Convention 2022, Jun-13-2022 . Venue: San Diego Convention Center, San Diego, Califor...

Positive

Exact Sciences Corporation completed the acquis...

2022-05-02 00:00:00

Exact Sciences Corporation entered into an agreement to acquire Omicera Diagnostics Gmbh for approximately $14.6 million on March 11, 2022. 26...

Neutral

Exact Sciences Corporation - Shareholder/Analyst Call

2022-04-29 10:40:00

AGM

Neutral

Exact Sciences Corporation, Annual General Meet...

2022-04-29 10:40:00

Exact Sciences Corporation, Annual General Meeting, Jun 09, 2022, at 10:00 Central Standard Time. Agenda: To elect the three nominees to our B...

Positive

American Society of Clinical Oncology Guideline...

2022-04-29 07:00:00

Exact Sciences Corp. announced that recommended use of its Oncotype DX Breast Recurrence Score® test in early-stage breast cancer patients has...

Positive

Exact Sciences Corporation Receives a Sharehold...

2022-04-29 06:40:00

On April 29, 2022, Exact Sciences Corporation announced that it has received a shareholder proposal from James McRitchie, requesting the Compa...

Positive

Exact Sciences Corporation Raises Revenue Guida...

2022-04-26 20:05:00

Exact Sciences Corporation raised revenue guidance for the year 2022. For the year, company anticipates revenue of $1,985 million to $2,032 mi...

Neutral

Exact Sciences Corporation, Q1 2022 Earnings Ca...

2022-04-08 10:00:00

Exact Sciences Corporation, Q1 2022 Earnings Call, Apr 26, 2022

Neutral

Exact Sciences Corporation to Report Q1, 2022 R...

2022-04-08 10:00:00

Exact Sciences Corporation announced that they will report Q1, 2022 results After-Market on Apr 26, 2022

Neutral

Blood Profiling Atlas in Cancer, BLOODPAC Summ...

2022-03-29 11:00:00

Blood Profiling Atlas in Cancer, BLOODPAC Summit 2022, Mar 31, 2022.

Neutral

Exact Sciences Corporation Presents at BLOODPAC...

2022-03-29 11:00:00

Exact Sciences Corporation Presents at BLOODPAC Summit 2022, Mar-31-2022 .

Neutral

Exact Sciences Corporation Presents at Bank of ...

2022-03-22 05:03:00

Exact Sciences Corporation Presents at Bank of America 2022 Healthcare Conference, May-11-2022 02:00 PM. Venue: Encore Hotel, 3121 Las Vegas B...

Neutral

Bank of America Corporation, Bank of America 20...

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vega...

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare...

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New Yor...

Neutral

The Goldman Sachs Group, Inc., Goldman Sachs 43...

2022-02-08 07:31:00

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Reso...

Neutral

Exact Sciences Corporation Approves Sixth Amend...

2022-01-28 21:01:00

Exact Sciences Corporation approved sixth amended and restated by-laws, effective January 28, 2022 . The sixth amended and restated by-laws am...

Neutral

William Blair & Company, L.L.C., William Blair’...

2022-01-25 11:00:00

William Blair & Company, L.L.C., William Blair’s 42nd Annual Growth Stock Conference 2022, Jun 06, 2022 through Jun 09, 2022. Venue: Loews Chi...

Neutral

American Society Of Clinical Oncology, Inc., th...

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago,...

Positive

Exact Sciences Corp. Announces New Data Present...

2021-12-08 08:42:00

Exact Sciences Corp. announced the presentation of new data at the 2021 San Antonio Breast Cancer Symposium (SABCS) supporting the clinical va...

Positive

Exact Sciences Corp. Announces Data from the Rx...

2021-12-02 08:00:00

Exact Sciences Corp. announced that data from the Rx for Positive Node, Endocrine Responsive Breast Cancer, or RxPONDER, trial were published ...

Neutral

Exact Sciences Corporation and Pfizer Inc. Ente...

2021-11-29 21:12:00

On November 29, 2021, Exact Sciences Corporation (the Company) and Pfizer Inc. (Pfizer) entered into an amendment (the Amendment) to the Amend...

Positive

Exact Sciences Corporation Announces Publicatio...

2021-11-23 14:08:00

Exact Sciences Corp. announced the publication of results underscoring the importance of adverse pathology as a reliable and critical endpoint...

Positive

Exact Sciences and Jefferson Health Commence Co...

2021-11-18 13:30:00

Exact Sciences Corp. announced an agreement with Jefferson Health (Jefferson) to conduct research on a new blood-based, multi-cancer earlier d...

Neutral

Biotechnology Innovation Organization, BIO Inte...

2021-11-09 17:12:00

Biotechnology Innovation Organization, BIO International Convention 2022, Jun 13, 2022 through Jun 16, 2022. Venue: San Diego Convention Cente...

Neutral

Phillips-Medisize and Exact Sciences Collaborat...

2021-11-03 12:45:00

Phillips-Medisize announced the successful collaboration with Exact Sciences, to advance early cancer detection. Fueled by a relentless pursui...

Neutral

Exact Sciences Corporation Revises Earnings Res...

2021-11-02 20:05:00

Exact Sciences Corporation revised earnings results for the full year 2021. For the year, the company anticipates revenue in the range of $1,7...

Neutral

Exact Sciences Corporation Presents at 12th Ann...

2021-11-01 10:00:00

Exact Sciences Corporation Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-16-2021 10:40 AM. Venue: London, United Kingdom.

Neutral

Exact Sciences Corporation Presents at Stifel 2...

2021-11-01 10:00:00

Exact Sciences Corporation Presents at Stifel 2021 Virtual Healthcare Conference, Nov-16-2021 03:20 PM. Venue: New York, New York, United States.

Neutral

Exact Sciences Corporation Presents at 4th Annu...

2021-11-01 10:00:00

Exact Sciences Corporation Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 11:20 AM.

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global...

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, Unit...

Positive

Exact Sciences Corp. Shares Data from Modeling ...

2021-10-25 21:33:00

Exact Sciences Corp. shared data from modeling analyses that demonstrate Cologuard (mt-sDNA), with its included patient navigation system, pro...

Neutral

Exact Sciences Corporation Presents at HLTH 202...

2021-10-14 16:17:00

Exact Sciences Corporation Presents at HLTH 2021 Conference, Oct-19-2021 03:40 PM. Venue: Boston, Massachusetts, United States. Speakers: Kevi...

Neutral

HLTH, LLC, HLTH 2021 Conference, Oct 17, 2021 t...

2021-10-08 12:30:00

HLTH, LLC, HLTH 2021 Conference, Oct 17, 2021 through Oct 20, 2021. Venue: Boston, Massachusetts, United States.

Neutral

Exact Sciences Corporation, Q3 2021 Earnings Ca...

2021-10-08 10:00:00

Exact Sciences Corporation, Q3 2021 Earnings Call, Nov 02, 2021

Neutral

Exact Sciences Corporation to Report Q3, 2021 R...

2021-10-08 10:00:00

Exact Sciences Corporation announced that they will report Q3, 2021 results After-Market on Nov 02, 2021

Positive

Exact Sciences Corporation and National Surgica...

2021-09-14 07:00:00

Exact Sciences Corp. announced that it has entered into a collaboration agreement with the National Surgical Adjuvant Breast and Bowel Project...

Neutral

Exact Sciences Corporation Presents at Baird Gl...

2021-08-26 17:20:00

Exact Sciences Corporation Presents at Baird Global Healthcare Conference 2021, Sep-15-2021 12:15 PM. Speakers: Jeffrey T. Elliott, Executive ...

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCO...

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Positive

Exact Sciences Receives Regulatory Approval for...

2021-08-16 10:00:00

Exact Sciences Corp. announced that Japan's Ministry of Health, Labor and Welfare has approved the Oncotype DX Breast Recurrence Score® Progra...

Positive

Exact Sciences Corp. Announces the Performance ...

2021-08-13 13:00:00

Exact Sciences Corp. announced that the performance of its Oncoguard™ Liver liquid biopsy test is now published online in the peer-reviewed jo...

Neutral

Robert W. Baird & Co. Incorporated, Baird Globa...

2021-08-10 13:03:00

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.

Positive

Exact Sciences Approaches Invitae

2021-08-09 09:56:00

Exact Sciences Corporation (NasdaqCM:EXAS) has approached Invitae Corporation (NYSE:NVTA), about a possible merger, according to people famili...

Positive

Exact Sciences Corporation Revised Revenue Guid...

2021-07-28 20:05:00

Exact Sciences Corporation revised revenue guidance for 2021. For the year, the company anticipates revenue of $1,705-$1,745 million. Updated ...

Positive

Exact Sciences Corporation (NasdaqCM:EXAS) acqu...

2021-07-28 00:00:00

Exact Sciences Corporation (NasdaqCM:EXAS) acquired remaining 10% interest in PFS Genomics Inc. on June 23, 2021. On May 3, 2021, Exact Scienc...

Neutral

Exact Sciences Corporation Presents at The UBS ...

2021-07-26 10:24:00

Exact Sciences Corporation Presents at The UBS Genomics 2.0 and Medtech Innovations Summit 2021, Aug-10-2021 06:00 PM. Venue: Montage Laguna B...

Neutral

Exact Sciences Corporation Presents at Wells Fa...

2021-07-22 14:24:00

Exact Sciences Corporation Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-09-2021 10:40 AM. Speakers: Erik Holznecht, Senior ...

Neutral

Wells Fargo Securities, LLC, Wells Fargo 2021 V...

2021-07-22 09:08:00

Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021.

Neutral

Exact Sciences Corporation to Report Q2, 2021 R...

2021-07-08 10:00:00

Exact Sciences Corporation announced that they will report Q2, 2021 results After-Market on Jul 28, 2021

Neutral

Exact Sciences Corporation, Q2 2021 Earnings Ca...

2021-07-08 10:00:00

Exact Sciences Corporation, Q2 2021 Earnings Call, Jul 28, 2021

Neutral

Stifel, Nicolaus & Company, Incorporated, Stife...

2021-07-08 08:44:00

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New ...

Positive

Exact Sciences Corporation(NasdaqCM:EXAS) added to Russell 2500 Value Index

2022-06-24 00:00:00

Exact Sciences Corporation(NasdaqCM:EXAS) added to Russell 2500 Value Index

Positive

Exact Sciences Corporation(NasdaqCM:EXAS) added to Russell 2500 Growth Index

2022-06-24 00:00:00

Exact Sciences Corporation(NasdaqCM:EXAS) added to Russell 2500 Growth Index

Positive

Exact Sciences Corporation(NasdaqCM:EXAS) added to Russell 2500 Index

2022-06-24 00:00:00

Exact Sciences Corporation(NasdaqCM:EXAS) added to Russell 2500 Index

Neutral

Declaration of Voting Results by Exact Sciences Corporation

2022-06-10 16:24:00

On June 10, 2022, Exact Sciences Corporation announced that at its annual general meeting of shareholders held on June 9, 2022, the Company's shareholders rejected a shareholder proposal concerning proxy access.

Neutral

Exact Sciences Corporation Presents at The 2022 ASCO Annual Meeting, Jun-03-2022 through Jun-07-2022

2022-05-29 01:15:00

Exact Sciences Corporation Presents at The 2022 ASCO Annual Meeting, Jun-03-2022 through Jun-07-2022. Venue: McCormick Place, Chicago, Illinois, United States. Presentation Date(s): Jun-04-2022. Jun-05-2022. Jun-06-2022.

Neutral

Nephron Research LLC, Nephron Liquid Biopsy Innovation Symposium 2022, Jun 21, 2022

2022-05-27 10:00:00

Nephron Research LLC, Nephron Liquid Biopsy Innovation Symposium 2022, Jun 21, 2022.

Neutral

Exact Sciences Corporation Presents at William Blair’s 42nd Annual Growth Stock Conference 2022, Jun-06-2022 03:40 PM

2022-05-27 10:00:00

Exact Sciences Corporation Presents at William Blair’s 42nd Annual Growth Stock Conference 2022, Jun-06-2022 03:40 PM. Venue: Loews Chicago Hotel, Chicago, Illinois, United States.

Neutral

Exact Sciences Corporation Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 01:00 PM

2022-05-27 10:00:00

Exact Sciences Corporation Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 01:00 PM. Venue: Marriott Marquis, New York City, New York, United States.

Neutral

Exact Sciences Corporation Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-13-2022 03:20 PM

2022-05-27 10:00:00

Exact Sciences Corporation Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-13-2022 03:20 PM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.

Neutral

Exact Sciences Corporation Presents at Nephron Liquid Biopsy Innovation Symposium 2022, Jun-21-2022 11:00 AM

2022-05-27 10:00:00

Exact Sciences Corporation Presents at Nephron Liquid Biopsy Innovation Symposium 2022, Jun-21-2022 11:00 AM. Speakers: Jake Orville, General Manager of Pipeline, Jeffrey T. Elliott, Executive VP, CFO & COO.

Neutral

Exact Sciences Corporation Presents at BIO International Convention 2022, Jun-13-2022

2022-05-14 02:46:00

Exact Sciences Corporation Presents at BIO International Convention 2022, Jun-13-2022 . Venue: San Diego Convention Center, San Diego, California, United States. Speakers: Jorge A. Garces, Chief Science Officer.

Positive

Exact Sciences Corporation completed the acquisition of Omicera Diagnostics Gmbh.

2022-05-02 00:00:00

Exact Sciences Corporation entered into an agreement to acquire Omicera Diagnostics Gmbh for approximately $14.6 million on March 11, 2022. 265,186 shares of Exact Sciences Corporation will issues as consideration to shareholders of Omicera Diagnostics Gmbh. Exact Sciences Corporation completed the acquisition of Omicera Diagnostics Gmbh on May 2, 2022.

Neutral

Exact Sciences Corporation - Shareholder/Analyst Call

2022-04-29 10:40:00

AGM

Neutral

Exact Sciences Corporation, Annual General Meeting, Jun 09, 2022

2022-04-29 10:40:00

Exact Sciences Corporation, Annual General Meeting, Jun 09, 2022, at 10:00 Central Standard Time. Agenda: To elect the three nominees to our Board of Directors nominated by our Board of Directors to serve for a three year term as Class I directors; to ratify the appointment of PricewaterhouseCoopers, LLP as our independent registered public accounting firm for 2022; to hold an advisory vote on executive compensation; to approve Amendment No. 1 to the Exact Sciences Corporation 2019 Omnibus Long-Term Incentive Plan; to approve the Amended and Restated Exact Sciences Corporation 2010 Employee Stock Purchase Plan; to hold a vote on a shareholder proposal concerning proxy access; and to transact such other business as may properly come before the annual meeting and any adjournments or postponements thereof.

Positive

American Society of Clinical Oncology Guidelines Strong Recommendation of Use of the Oncotype DX Breast Recurrence Score® Test of Exact Sciences Corp. in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients

2022-04-29 07:00:00

Exact Sciences Corp. announced that recommended use of its Oncotype DX Breast Recurrence Score® test in early-stage breast cancer patients has been expanded by the American Society of Clinical Oncology (ASCO) in its 2022 Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer guideline update. The test is now recommended for use in postmenopausal patients with up to three positive axillary lymph nodes and is the only test recommended for use in premenopausal patients with node-negative disease. Importantly, the test is recommended irrespective of clinical risk, and Oncotype DX® is the most strongly recommended with the higher evidence quality of all multigene tests included in the guidelines. The updated guidelines incorporate results from the RxPONDER trial published in The New England Journal of Medicine.ii The study demonstrated that the test identifies a majority of early-stage breast cancer patients with one to three positive nodes who may be spared chemotherapy. Postmenopausal women with Oncotype DX Breast Recurrence Score® results of 0 to 25 did not show benefit from the addition of chemotherapy to hormone therapy. Premenopausal women with a Recurrence Score result of 0 to 25 received a 2.4% benefit from chemotherapy in terms of distant recurrence at five years. Approximately one-third of patients diagnosed with hormone receptor (HR)-positive, HER2-negative early breast cancer have a tumor that has spread to their lymph nodes. The vast majority of these patients currently receive chemotherapy even though approximately 85% of them have Recurrence Score results of 0 to 25. In addition, about two out of three early-stage breast cancer patients are postmenopausal. The Oncotype DX portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. In breast cancer, the Oncotype DX Breast Recurrence Score test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the Oncotype DX Breast DCIS Score™ test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. For patients with advanced and metastatic cancer, the company offers the Oncotype MAP™ Pan-Cancer Tissue test, a rapid, comprehensive tumor profiling panel, which provides results in three to five business days[viii] and allows physicians to understand a patient's tumor profile and recommend actionable targeted therapies or clinical trials. With more than 1 million patients tested in more than 90 countries, the Oncotype DX tests have redefined medicine by making genomics a critical part of cancer diagnosis and treatment.

Positive

Exact Sciences Corporation Receives a Shareholder Proposal from James McRitchie

2022-04-29 06:40:00

On April 29, 2022, Exact Sciences Corporation announced that it has received a shareholder proposal from James McRitchie, requesting the Company board of directors take the steps necessary to enable shareholders, without limits on group size, to aggregate their shares to equal 3% of the Company stock owned continuously for 3-years to enable shareholder proxy access with the following essential provision. In addition, the Company urged the shareholders to vote against the shareholder proposal at its annual general meeting of shareholders scheduled to be held on June 9, 2022.

Positive

Exact Sciences Corporation Raises Revenue Guidance for the Year 2022

2022-04-26 20:05:00

Exact Sciences Corporation raised revenue guidance for the year 2022. For the year, company anticipates revenue of $1,985 million to $2,032 million during 2022. Revenue guidance has been raised and narrowed toward the high end of the previously expected range of $1,975 million to $2,027 million.

Neutral

Exact Sciences Corporation, Q1 2022 Earnings Call, Apr 26, 2022

2022-04-08 10:00:00

Exact Sciences Corporation, Q1 2022 Earnings Call, Apr 26, 2022

Neutral

Exact Sciences Corporation to Report Q1, 2022 Results on Apr 26, 2022

2022-04-08 10:00:00

Exact Sciences Corporation announced that they will report Q1, 2022 results After-Market on Apr 26, 2022

Neutral

Blood Profiling Atlas in Cancer, BLOODPAC Summit 2022, Mar 31, 2022

2022-03-29 11:00:00

Blood Profiling Atlas in Cancer, BLOODPAC Summit 2022, Mar 31, 2022.

Neutral

Exact Sciences Corporation Presents at BLOODPAC Summit 2022, Mar-31-2022

2022-03-29 11:00:00

Exact Sciences Corporation Presents at BLOODPAC Summit 2022, Mar-31-2022 .

Neutral

Exact Sciences Corporation Presents at Bank of America 2022 Healthcare Conference, May-11-2022 02:00 PM

2022-03-22 05:03:00

Exact Sciences Corporation Presents at Bank of America 2022 Healthcare Conference, May-11-2022 02:00 PM. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States. Speakers: Jeffrey T. Elliott, Executive VP, CFO & COO, Kevin T. Conroy, Chairman of the Board, President & CEO.

Neutral

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022

2022-02-17 10:42:00

Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Neutral

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022

2022-02-08 07:31:00

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.

Neutral

Exact Sciences Corporation Approves Sixth Amended and Restated By-Laws

2022-01-28 21:01:00

Exact Sciences Corporation approved sixth amended and restated by-laws, effective January 28, 2022 . The sixth amended and restated by-laws amend and restate in their entirety the company’s by-laws to, among other things, amend article 1, section 10 to implement a proxy access bylaw. Article I, Section 1.10B of the sixth amended and restated by-laws permits a stockholder, or a group of up to 20 stockholders, owning 3% or more of the company’s outstanding common stock continuously for at least three years to nominate and include in the company’s proxy materials directors constituting up to the greater of two individuals or 20% of the board, provided that the stockholder and the nominee satisfy the requirements specified in article I, section 1.10B. The sixth amended and restated by-laws also contain conforming, clarifying and updating changes to supplement the company’s proxy access by-law, as well as certain other non-substantive updates and revisions.

Neutral

William Blair & Company, L.L.C., William Blair’s 42nd Annual Growth Stock Conference 2022, Jun 06, 2022 through Jun 09, 2022

2022-01-25 11:00:00

William Blair & Company, L.L.C., William Blair’s 42nd Annual Growth Stock Conference 2022, Jun 06, 2022 through Jun 09, 2022. Venue: Loews Chicago Hotel, Chicago, Illinois, United States.

Neutral

American Society Of Clinical Oncology, Inc., the 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago, Illinois, United States.

Positive

Exact Sciences Corp. Announces New Data Presented At SABCS 2021 Strengthen Value of Oncotype Dx Breast Recurrence Score Test to Inform Clinical Decision-Making

2021-12-08 08:42:00

Exact Sciences Corp. announced the presentation of new data at the 2021 San Antonio Breast Cancer Symposium (SABCS) supporting the clinical value of the Oncotype DX Breast Recurrence Score test. New analyses presented at the meeting include an oral presentation of updated data from the RxPONDER study led by the independent SWOG Cancer Research Network, and sponsored by the National Cancer Institute (NCI). Following the recent publication of initial study results in The New England Journal of Medicine, updated data were presented in an oral session at SABCS by Dr. Kevin Kalinsky, study lead investigator. In an analysis with longer follow-up (median 6.1 years), the investigators reported that postmenopausal women with 1-3 positive nodes and Recurrence Score results 0-25 continue to not benefit from adjuvant chemotherapy. In addition, a new analysis of distant recurrence-free interval (defined as time to distant recurrence or death from breast cancer) showed that premenopausal women with Recurrence Score results 0-13 received a modest 2.3% absolute benefit at five years. For those with Recurrence Score results 14-25 the benefit was 2.8%. Approximately one-third of patients diagnosed with hormone receptor (HR)-positive, HER2-negative early breast cancer have a tumor that has spread to their lymph nodes. The vast majority of these patients currently receive chemotherapy even though approximately 85% of them have Recurrence Score results 0 to 25. In addition, approximately two out of three early-stage breast cancer patients are postmenopausal. The study, presented at SABCS in a poster session, applied the 16-gene radiation therapy signature to 132 patients enrolled in the Princess Margaret Trial, which randomized patients ages 50 or older to radiotherapy and tamoxifen or tamoxifen alone after breast conserving surgery. The results, in a treatment cohort in line with the current standard of care, support previous validation study data[vii] suggesting that the 16-gene radiation therapy signature may be used to identify patients with a low risk of locoregional recurrence who will not experience significant benefit from adjuvant radiotherapy. The 16-gene radiation therapy signature was developed by PFS Genomics, a company acquired by Exact Sciences earlier this year.

Positive

Exact Sciences Corp. Announces Data from the Rx for Positive Node, Endocrine Responsive Breast Cancer or RxPONDER, Trial Publish in the New England Journal of Medicine

2021-12-02 08:00:00

Exact Sciences Corp. announced that data from the Rx for Positive Node, Endocrine Responsive Breast Cancer, or RxPONDER, trial were published in The New England Journal of Medicine.i The study, led by the independent SWOG Cancer Research Network and sponsored by the National Cancer Institute (NCI), successfully defined the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Oncotype DX Breast Recurrence Score® results of 0 to 25. Initial results from RxPONDER were reported at the 2020 San Antonio Breast Cancer Symposium (SABCS). The findings have now been confirmed in this peer-reviewed publication. In the study, postmenopausal women with 1 to 3 positive nodes and Recurrence Score® results of 0 to 25 showed no benefit from chemotherapy after a median of five years of follow-up, meaning they can potentially avoid negative side effects of the treatment. Importantly, no chemotherapy benefit was observed regardless of the number of affected nodes, tumor grade or size. In premenopausal women with 1 to 3 positive nodes, a statistically significant chemotherapy benefit was observed. Approximately one-third of patients diagnosed with hormone receptor (HR)-positive, HER2-negative early breast cancer have a tumor that has spread to their lymph nodes. The vast majority of these patients currently receive chemotherapy even though approximately 85% of them have Recurrence Score results of 0 to 25. In addition, approximately two out of three early-stage breast cancer patients are postmenopausal. Based on the RxPONDER results, the National Comprehensive Cancer Network® (NCCN®) updated its guidelines for breast cancer and recognized the Oncotype DX Breast Recurrence Score test as the only test that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with 1 to 3 positive axillary lymph nodes, including micrometastases. The Oncotype DX test is now the only test classified as "preferred" with the highest level of evidence for node-negative and postmenopausal node-positive (1 to 3 positive nodes) patients. In addition, NCCN recommends considering the test to assess prognosis in premenopausal node-positive patients who are candidates for chemotherapy. One of the largest clinical trials in node-positive, HR-positive, HER2-negative early breast cancer, RxPONDER enrolled more than 5,000 women with up to three positive nodes. The prospective, randomized Phase III study was conducted at 632 sites in nine countries – the United States, Canada, Mexico, Colombia, Ireland, France, Spain, South Korea and Saudi Arabia. Women with a Recurrence Score result of 0 to 25 were randomized to treatment with hormone therapy alone or chemotherapy followed by hormone therapy. Randomized patients were stratified based on their Recurrence Score result, menopausal status and type of lymph node surgery. Further analyses and additional patient follow up are planned by the SWOG investigators.

Neutral

Exact Sciences Corporation and Pfizer Inc. Enter into an Amendment to the Amended & Restated Cologuard Promotion Agreement

2021-11-29 21:12:00

On November 29, 2021, Exact Sciences Corporation (the Company) and Pfizer Inc. (Pfizer) entered into an amendment (the Amendment) to the Amended & Restated Cologuard ® Promotion Agreement effective October 6, 2020, by and between the Company and Pfizer (the Promotion Agreement). The Amendment provides that after November 30, 2021, Pfizer will no longer promote the Company’s Cologuard colorectal cancer screening test (the Product) to health care providers. As reported on a Form 8-K filed by the Company on September 15, 2021, the Company recently hired approximately 400 former Pfizer sales representatives to promote the Product to health care providers. The Amendment provides that the Company will pay Pfizer a total of $35,900,000 in three installments during the second, third, and fourth quarters of 2022. The Amendment eliminates the Company’s obligation to pay Pfizer royalties or other fees except for certain media fees, advertising fees, and any detail fees owed to Pfizer for promoting the Product prior to November 30, 2021. Pursuant to the Promotion Agreement, as amended, Pfizer will continue to purchase certain advertising for the Product on behalf of the Company through the third quarter of 2022 and will provide support in transitioning responsibilities for purchasing such advertising to the Company.

Positive

Exact Sciences Corporation Announces Publication of Results Underscoring the Importance of Adverse Pathology

2021-11-23 14:08:00

Exact Sciences Corp. announced the publication of results underscoring the importance of adverse pathology as a reliable and critical endpoint for risk-assessment in clinically low-risk prostate cancer patients. Published in Urologic Oncology: Seminars and Original Investigations and led by study collaborators at the Cleveland Clinic, the findings showed that men who were discovered to have adverse pathology, following a radical prostatectomy, were 10 times more likely to develop metastatic disease and eight times more likely to die from their prostate cancer than those with favorable pathology, up to a 20-year follow up. The findings strongly support the clinical use of the Oncotype DX Genomic Prostate Score (GPS™) test, the only commercial genomic test that was specifically developed to improve assessment of a patient's risk of adverse pathology, beyond clinical factors alone, and optimized to perform in biopsy samples. In the study, analyses were performed on a sample of 428 patients, largely clinically low and intermediate risk (10% being clinically high risk), treated with radical prostatectomy (RP) between 1987 and 2004. Adverse pathology was defined as either high-grade or high-stage disease (Gleason Grade 3 or above and/or non-organ confined disease, pT3 or higher). Patients with no AP at surgery had a nearly zero risk of metastasis and death even at 20 years, while metastatic and death events rose immediately and sharply in the group of patients who had adverse pathology. The Oncotype DX GPS test is backed by a robust body of clinical evidence in more than 9,000 men and Exact Sciences is committed to further strengthening the data supporting the expanded clinical utility of the test. Recently, the company has redesigned its patient test reports to reflect new clinical evidence and to answer the different clinical needs in low- and high-risk patients. With two tailored reports, the Oncotype DX GPS assay provides critical information for when active surveillance may be an appropriate decision in lower-risk patients and provides risk estimates to help inform treatment decisions for higher risk patients. The patient-friendly resources help facilitate discussions between patients and their healthcare practitioners by consolidating key prostate cancer characteristics in a single document for ease of reference during treatment management conversations. The new high-risk reports are currently available, and the new low-risk reports will launch December 2021.

Positive

Exact Sciences and Jefferson Health Commence Collaboration on Multi-Cancer Earlier Detection

2021-11-18 13:30:00

Exact Sciences Corp. announced an agreement with Jefferson Health (Jefferson) to conduct research on a new blood-based, multi-cancer earlier detection (MCED) test. This unique effort will engage primary care and specialty providers, care coordinators, and patients from diverse populations across the Jefferson enterprise in research that aims to evaluate MCED test safety and efficacy and help determine how to facilitate the implementation of effective MCED testing in the future. Jefferson is conducting developmental research on patient and provider engagement and plans to participate in Exact Sciences' FDA registration study for its MCED test. Exact Sciences and Jefferson also plan to publish results of their work in this important area.

Neutral

Biotechnology Innovation Organization, BIO International Convention 2022, Jun 13, 2022 through Jun 16, 2022

2021-11-09 17:12:00

Biotechnology Innovation Organization, BIO International Convention 2022, Jun 13, 2022 through Jun 16, 2022. Venue: San Diego Convention Center, San Diego, California, United States.

Neutral

Phillips-Medisize and Exact Sciences Collaborate to Fight Colorectal Cancer

2021-11-03 12:45:00

Phillips-Medisize announced the successful collaboration with Exact Sciences, to advance early cancer detection. Fueled by a relentless pursuit for smarter, earlier life-changing answers about cancer, Exact Sciences developed Cologuard®, the first and only FDA-approved non invasive stool DNA screening test for colorectal cancer. This mission aligned seamlessly with Phillips-Medisize's decades of innovation and world-class product design, development and manufacturing capabilities. Unprecedented levels of supply chain flexibility enabled Exact Sciences to acquire all the parts, products and raw materials needed to rapidly scale kit production. Phillips-Medisize located and validated alternate supply sources, conducted risk assessments and forecasting, as well as sourcing and procurement plans to protect against unplanned disruptions. The organization's ability to increase safety stock, hold spare parts and leverage its buying power helped Exact Sciences attain much-needed supplies and raw materials to meet rapidly increasing demand, such as resin.

Neutral

Exact Sciences Corporation Revises Earnings Results for the Full Year 2021

2021-11-02 20:05:00

Exact Sciences Corporation revised earnings results for the full year 2021. For the year, the company anticipates revenue in the range of $1,722 million to $1,737 million during 2021. Updated revenue guidance has been narrowed toward the high end of previously expected range of $1,705 million to $1,745 million.

Neutral

Exact Sciences Corporation Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-16-2021 10:40 AM

2021-11-01 10:00:00

Exact Sciences Corporation Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-16-2021 10:40 AM. Venue: London, United Kingdom.

Neutral

Exact Sciences Corporation Presents at Stifel 2021 Virtual Healthcare Conference, Nov-16-2021 03:20 PM

2021-11-01 10:00:00

Exact Sciences Corporation Presents at Stifel 2021 Virtual Healthcare Conference, Nov-16-2021 03:20 PM. Venue: New York, New York, United States.

Neutral

Exact Sciences Corporation Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 11:20 AM

2021-11-01 10:00:00

Exact Sciences Corporation Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov-30-2021 11:20 AM.

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.

Positive

Exact Sciences Corp. Shares Data from Modeling Analyses that Demonstrate Cologuard

2021-10-25 21:33:00

Exact Sciences Corp. shared data from modeling analyses that demonstrate Cologuard (mt-sDNA), with its included patient navigation system, provides a greater reduction in incidence and mortality from colorectal cancer (CRC) compared to annual fecal immunochemical test (FIT), when it included outreach, with or without a mailed annual FIT, using real world adherence rates in a simulated Medicaid population. Cologuard remained cost-effective in all the real-world adherence scenarios modeled. The modeling analyses were consistent with the CISNET Colorectal Working Group models when using 100% adherence rates. The Exact Sciences Laboratories Patient Navigation Program features on-demand phone support, reminder phone calls, texts and emails at no additional cost with each Cologuard test ordered. These new data, generated from the CRC-AIM microsimulation model, will be presented in an ACG Presidential Award-winning poster titled, "Cost-Effectiveness of Stool-Based Colorectal Cancer Screening Using Reported Real-World Adherence Rates in a Medicare Population.

Neutral

Exact Sciences Corporation Presents at HLTH 2021 Conference, Oct-19-2021 03:40 PM

2021-10-14 16:17:00

Exact Sciences Corporation Presents at HLTH 2021 Conference, Oct-19-2021 03:40 PM. Venue: Boston, Massachusetts, United States. Speakers: Kevin T. Conroy, Chairman of the Board, President & CEO.

Neutral

HLTH, LLC, HLTH 2021 Conference, Oct 17, 2021 through Oct 20, 2021

2021-10-08 12:30:00

HLTH, LLC, HLTH 2021 Conference, Oct 17, 2021 through Oct 20, 2021. Venue: Boston, Massachusetts, United States.

Neutral

Exact Sciences Corporation, Q3 2021 Earnings Call, Nov 02, 2021

2021-10-08 10:00:00

Exact Sciences Corporation, Q3 2021 Earnings Call, Nov 02, 2021

Neutral

Exact Sciences Corporation to Report Q3, 2021 Results on Nov 02, 2021

2021-10-08 10:00:00

Exact Sciences Corporation announced that they will report Q3, 2021 results After-Market on Nov 02, 2021

Positive

Exact Sciences Corporation and National Surgical Adjuvant Breast and Bowel Project Announce Clinical Validation Study to Detect Minimal Residual Disease in Colorectal Cancer Patients

2021-09-14 07:00:00

Exact Sciences Corp. announced that it has entered into a collaboration agreement with the National Surgical Adjuvant Breast and Bowel Project, a cooperative group founded by the National Cancer Institute. Working together, Exact Sciences and the NSABP plan to conduct a prospective, multicenter validation study with stage II and III colorectal cancer patients, demonstrating the ability of Exact Sciences' ctDNA test to detect MRD. The study, called CORRECT-MRD II, is expected to enroll approximately 750 patients at 35 study sites in the U.S. and Canada and is part of Exact Sciences' global initiative to generate clinical validation data for its tumor-informed MRD liquid biopsy test. Exact Sciences is well-positioned to bring a highly sensitive MRD solution to patients in need. Its recent exclusive license of the Targeted Digital Sequencing blood biopsy technology and acquisition of Ashion Analytics help prepare Exact Sciences to develop a differentiated patient-specific solution in MRD testing. With proven evidence-generation abilities and deep commercial relationships, Exact Sciences has the capability to bring its solution to patients and providers in the U.S. quickly and efficiently. In addition, the patient specific MRD test may have the potential to be synergistic with the predictive and prognostic insights provided by the Exact Sciences' Oncotype portfolio to further inform treatment decisions to help improve patient outcomes. The company aims to explore the full potential of its MRD technology across all solid tumor types. Exact Sciences and the NSABP are also working with patient advocacy organization Fight Colorectal Cancer (Fight CRC) to help inform MRD study designs and identify potential barriers to study participation, particularly in underserved populations. This joint effort will help ensure patient recruitment and patient-facing study materials are clear and sensitive to diverse cultures and socioeconomic backgrounds.

Neutral

Exact Sciences Corporation Presents at Baird Global Healthcare Conference 2021, Sep-15-2021 12:15 PM

2021-08-26 17:20:00

Exact Sciences Corporation Presents at Baird Global Healthcare Conference 2021, Sep-15-2021 12:15 PM. Speakers: Jeffrey T. Elliott, Executive VP, CFO & COO, Kevin T. Conroy, Chairman of the Board, President & CEO.

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Positive

Exact Sciences Receives Regulatory Approval for the Oncotype DX Breast Recurrence Score® Program in Japan

2021-08-16 10:00:00

Exact Sciences Corp. announced that Japan's Ministry of Health, Labor and Welfare has approved the Oncotype DX Breast Recurrence Score® Program. The test helps guide chemotherapy treatment recommendations and provides risk of distant recurrence in patients with hormone receptor-positive, HER2-negative early-stage breast cancer with up to three positive lymph nodes. MHLW approval is a critical step in making Oncotype DX® accessible to breast cancer patients in Japan. Breast cancer is the most common cancer in Japanese women, and more than 90,000 new breast cancer cases were diagnosed in Japan in 2020. The Oncotype DX Breast Recurrence Score Program approved in Japan combines the Oncotype DX Breast Recurrence Score® test and software developed for the Japanese market. Exact Sciences plans to pursue coverage under Japan's universal healthcare insurance system and launch the test through its Japanese affiliate, Exact Sciences K.K. The Oncotype DX test provides information allowing doctors and patients to personalize treatment plans with greater confidence. While chemotherapy is routinely offered, research shows that only a minority of patients with early-stage breast cancer will actually benefit. Oncotype DX is the only test validated to determine which patients will benefit from chemotherapy and provides critical information beyond traditional prognostic factors. The test is supported by prospective outcomes data from the TAILOR and RxPONDER studies, which show that most patients with either node-negative or node-positive disease can be spared chemotherapy when decisions are guided by Oncotype DX.

Positive

Exact Sciences Corp. Announces the Performance of its Oncoguard™ Liver Liquid Biopsy Test

2021-08-13 13:00:00

Exact Sciences Corp. announced that the performance of its Oncoguard™ Liver liquid biopsy test is now published online in the peer-reviewed journal Clinical Gastroenterology and Hepatology (CGH). The test delivers 82% early-stage sensitivity, and an overall 88% sensitivity and 87% specificity1 for the detection of hepatocellular carcinoma (HCC), the leading form of liver cancer. The newly published clinical validation study details the performance of the Oncoguard™ Liver test in a group representative of the U.S. population recommended for HCC surveillance. The sensitivity demonstrated by the Oncoguard™ Liver test highlights the potential for significant advances in early-stage HCC detection. Early-stage detection can increase five-year survival rates for HCC from less than 12%, to upwards of 70%.

Neutral

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021

2021-08-10 13:03:00

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.

Positive

Exact Sciences Approaches Invitae

2021-08-09 09:56:00

Exact Sciences Corporation (NasdaqCM:EXAS) has approached Invitae Corporation (NYSE:NVTA), about a possible merger, according to people familiar with the matter. The companies are not in active talks and should a deal be reached it would likely be a low-premium, all-stock merger, the people said, asking not to be identified because the matter isn’t public. There is no guarantee that an agreement will be announced. A representatives for Exact Sciences and Invitae declined to comment.

Positive

Exact Sciences Corporation Revised Revenue Guidance for 2021

2021-07-28 20:05:00

Exact Sciences Corporation revised revenue guidance for 2021. For the year, the company anticipates revenue of $1,705-$1,745 million. Updated guidance is an increase from previously expected revenue of $1,690-$1,735 million.

Positive

Exact Sciences Corporation (NasdaqCM:EXAS) acquired remaining 10% interest in PFS Genomics Inc.

2021-07-28 00:00:00

Exact Sciences Corporation (NasdaqCM:EXAS) acquired remaining 10% interest in PFS Genomics Inc. on June 23, 2021. On May 3, 2021, Exact Sciences Corporation acquired 90% of the outstanding capital stock of PFS Genomics Inc. The combined deal value for both the transaction is $33.6 million. Exact Sciences Corporation (NasdaqCM:EXAS) completed the acquisition of remaining 10% interest in PFS Genomics Inc. on June 23, 2021.

Neutral

Exact Sciences Corporation Presents at The UBS Genomics 2.0 and Medtech Innovations Summit 2021, Aug-10-2021 06:00 PM

2021-07-26 10:24:00

Exact Sciences Corporation Presents at The UBS Genomics 2.0 and Medtech Innovations Summit 2021, Aug-10-2021 06:00 PM. Venue: Montage Laguna Beach, 30801 S Coast Hwy, Laguna Beach, California, United States. Speakers: Brian Baranick, Strategy & Business Development, Jeffrey T. Elliott, Executive VP, CFO & COO, Jorge Garce, Senior Vice President, Chief Science Officer.

Neutral

Exact Sciences Corporation Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-09-2021 10:40 AM

2021-07-22 14:24:00

Exact Sciences Corporation Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-09-2021 10:40 AM. Speakers: Erik Holznecht, Senior Investor Relations Associate, Jeffrey T. Elliott, Executive VP, CFO & COO, Megan Jones, Associate Manager of Investor Relations.

Neutral

Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021

2021-07-22 09:08:00

Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021.

Neutral

Exact Sciences Corporation to Report Q2, 2021 Results on Jul 28, 2021

2021-07-08 10:00:00

Exact Sciences Corporation announced that they will report Q2, 2021 results After-Market on Jul 28, 2021

Neutral

Exact Sciences Corporation, Q2 2021 Earnings Call, Jul 28, 2021

2021-07-08 10:00:00

Exact Sciences Corporation, Q2 2021 Earnings Call, Jul 28, 2021

Neutral

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021

2021-07-08 08:44:00

Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New York, United States.

Fundamental Summary

At a high level, the metrics from Exact Sciences's Q1 financial report release were demonstrably negative. Specifically, their growth, value, and income factors indicate an execution challenge when it comes to generating exciting and consistent growth. These troubling results make a strong case for underperformance and for anticipating a significant downside. Therefore, we assessed them with a rating of 46 and a UNDERPERFORM recommendation.

Exact Sciences reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was USD 486.57 million compared to USD 402.08 million a year ago. Net loss was USD 180.94 million compared to USD 31.16 million a year ago. Basic loss per share from continuing operations was USD 1.04 compared to USD 0.18 a year ago. Diluted loss per share from continuing operations was USD 1.04 compared to USD 0.18 a year ago.

Business Description

Exact Sciences provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company’s pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Sector Overview

Exact Sciences is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Exact Sciences's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 6,490.5 -2.9% 58
Liabilities 3,232.3 -2.0% 57
Price to Book 2.6 -34.9% 52
Cash & Equivalents 189.8 -39.8% 42
Equity 3,258.2 -3.8% 45
EBITDA -484.7 -3.0% 67
Total Revenues 1,851.6 4.8% 57
Parameter Value Change Score
Return on Equity -21.6 -1.9% 54
Net Cashflow -914.0 22.3% 53
Capital Expenditure -131.5 3.2% 80
Asset Turnover 0.3 -8.0% 46
Free Cashflow -1.9 -37.8% 45

* All values are TTM

The below chart reflects Exact Sciences's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Exact Sciences's peer average final assessment score stands on 63.0, Exact Sciences's score is 46.

  •  EXAS
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 0 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 1 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 2 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 3 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 4 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 5 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 6 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 7 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 8 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 9 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 10 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 11 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 12 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 13 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 14 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 15 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 16 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 17 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 18 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 20 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 21 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 22 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 24 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 25 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 26 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 27 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 28 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 29 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 30 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 31 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 32 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 33 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 34 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 35 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 36 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 37 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 39 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 40 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 41 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 42 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 43 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 44 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 45 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 47 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 48 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 50 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 51 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 52 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 53 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 54 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 55 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 56 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 57 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 58 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 59 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 60 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 61 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 62 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 63 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 64 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 65 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 66 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 68 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 69 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 70 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 71 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 72 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 73 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 74 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 75 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 76 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 77 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 78 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 79 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 80 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 81 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 82 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 83 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 84 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 86 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 87 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 88 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 89 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 90 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 91 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 92 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 93 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Exact Sciences's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Exact Sciences's stock doesn't strongly signal being overbought or oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 31.

Bearish 31
Close Price 41.11
52W Low 35.61
52W High 128.14
5D MA 42.42
50D MA 50.68
200D MA 74.05
MACD -2.85
RSI 63.94
STOCH 39.63

Balance Sheet Analysis

A few metrics from Exact Sciences's current balance sheet were especially concerning: Cash & Equivalents and Equity. Exact Sciences's management did a relatively poor job managing cash and cash equivalents, which now sit at 189.8 and represents a -39.8% change from the last reporting period. Their anemic growth in cash and cash equivalents, specifically in contrast to their industry peers' performance, should hurt their stock price. Consequently, their cash and cash equivalents movement received a grade of 42. Also, Exact Sciences reported weak equity changes momentum this period. At filing, equity was reported as 3258.2, representing -3.8% change from the previous report. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. Their equity metrics appear unremarkable relative to their peers. Therefore, their equity movement component earned a score of 45. On the other hand, Assets, jumped out as looking rather positive. The company's assets section could set high expectations for Exact Sciences's future attractiveness, as they went to 6490.5, which is a -2.9% change from the last period. This growth should support upward pressure on its's stock price, which better captures their intrinsic value. Therefore, its asset component earned a score of 58. Therefore, the company's balance sheet earned a grade of 47.

Parameter Value Change Score
Assets 6,490.5 -2.9% 58
Liabilities 3,232.3 -2.0% 57
Price to Book 2.6 -34.9% 52
Cash & Equivalents 189.8 -39.8% 42
Equity 3,258.2 -3.8% 45
* All values are TTM

The below chart describes Exact Sciences's performance as reflected on its balance sheet with respect to its peers. While Exact Sciences received a balance sheet score of 47, the average of its peers stands on 62.0.

  •  EXAS
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 0 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 1 1
Vericel Corporation 1.1B 51 65 56 53 61 57 2 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 3 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 4 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 5 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 6 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 7 1
Immatics N.V. 538.7M 56 70 84 95 73 76 8 1
Agenus Inc. 520.5M 73 62 37 55 60 54 9 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 10 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 11 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 12 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 13 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 14 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 15 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 16 1
Amgen Inc. 130.1B 72 68 86 53 62 69 17 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 18 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 20 1
BioNTech SE 34.0B 75 69 64 97 73 75 21 1
Seagen Inc. 32.9B 59 68 55 43 66 61 22 1
Biogen Inc. 29.7B 57 72 92 50 76 76 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 24 1
Incyte Corporation 16.8B 71 72 95 82 79 83 25 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 26 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 27 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 28 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 29 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 30 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 31 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 32 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 33 1
Alkermes plc 5.0B 63 66 46 54 71 62 34 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 35 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 36 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 37 1
Natera, Inc. 3.6B 73 65 43 95 42 54 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 39 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 40 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 41 1
CureVac N.V. 2.6B 49 64 75 52 52 57 42 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 43 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 44 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 45 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 47 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 48 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 50 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 51 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 52 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 53 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 54 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 55 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 56 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 57 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 58 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 59 1
CareDx, Inc 1.2B 54 67 52 39 51 52 60 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 61 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 62 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 63 1
MannKind Corporation 957.2M 79 59 50 40 64 57 64 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 65 1
Merus N.V. 941.6M 59 68 50 83 81 70 66 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 68 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 69 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 70 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 71 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 72 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 73 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 74 1
Geron Corporation 566.2M 69 72 37 59 62 60 75 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 76 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 77 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 78 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 79 1
Affimed N.V. 415.0M 56 66 63 56 47 54 80 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 81 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 82 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 83 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 84 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 86 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 87 1
AC Immune SA 299.8M 84 64 47 53 75 68 88 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 89 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 90 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 91 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 92 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 93 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Exact Sciences seems to be balancing strong EBITDA and Revenue Efficiency along with an overall impressive positive income statement. Exact Sciences's management did a remarkable job this period managing its EBITDA. In terms of the raw numbers, EBITDA was reported as -484.7, which represents a -3.0% change from the last period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. The company is headed in the right direction regarding EBITDA, exhibiting efficient capital controls and strong overall financial performance. Consequently, their EBITDA movement received a grade of 67. Also, Exact Sciences's financials reveal an interesting trend for their revenue efficiency. This parameter often affects companies in the same industry and market capitalization by up to 13.1%. Their impressive revenue efficiency is even more impressive relative to its peers and competitors in the current market. Consequently, their revenue efficiency received a grade of 57. That said, one metric, Return Factors, stood out as strongly negative. Return factors metrics and ratios were disappointing in this report. Exact Sciences reported a return on equity (ROE) ratio of -21.6, representing a change of -1.9% from the last report.change of -1.9% from the previous period. This metric might have a 3.6 percent impact on companies in the same industry and with the same market capitalization. They does not yet appear to be headed in the right direction regarding these return on equity and return on assets metrics. Its return factors (ROA & ROE) components, therefore, received a grade of 54. Because its management is doing an excellent job managing these critical metrics, the income statement was given a score of 62.

Parameter Value Change Score
EBITDA -484.7 -3.0% 67
Total Revenues 1,851.6 4.8% 57
Return on Equity -21.6 -1.9% 54
* All values are TTM

The below chart describes Exact Sciences's performance as reflected on its income statement with respect to its peers. While Exact Sciences received a income statement score of 62 , the average of its peers stands on 65.0.

  •  EXAS
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Dynavax Technologies Corporation 1.5B 51 69 77 67 0 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 1 1
Vericel Corporation 1.1B 76 44 82 56 2 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 3 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 4 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 5 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 6 1
CTI BioPharma Corp. 603.6M 84 50 62 59 7 1
Immatics N.V. 538.7M 37 93 53 77 8 1
Agenus Inc. 520.5M 57 83 45 74 9 1
Vaxart, Inc. 440.0M 99 51 72 68 10 1
MiMedx Group, Inc. 391.5M 87 43 83 59 11 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 12 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 13 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 14 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 15 1
DermTech, Inc. 165.3M 49 48 78 52 16 1
Amgen Inc. 130.1B 74 75 64 78 17 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 18 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 20 1
BioNTech SE 34.0B 41 89 75 79 21 1
Seagen Inc. 32.9B 54 65 70 62 22 1
Biogen Inc. 29.7B 90 57 73 70 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 24 1
Incyte Corporation 16.8B 59 77 60 73 25 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 26 1
United Therapeutics Corporation 10.6B 57 91 54 82 27 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 28 1
Exelixis, Inc. 6.7B 54 91 54 81 29 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 30 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 31 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 32 1
Ascendis Pharma A/S 5.2B 38 68 46 54 33 1
Alkermes plc 5.0B 69 55 81 62 34 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 35 1
Novavax, Inc. 4.0B 41 89 54 75 36 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 37 1
Natera, Inc. 3.6B 52 51 78 52 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 39 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 40 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 41 1
CureVac N.V. 2.6B 45 83 71 74 42 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 43 1
Insmed Incorporated 2.4B 51 58 73 57 44 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 45 1
Abgenix Inc. 2.1B 47 47 47 47 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 47 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 48 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 50 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 51 1
Xencor, Inc. 1.6B 42 94 52 79 52 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 53 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 54 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 55 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 56 1
Veracyte, Inc. 1.4B 45 63 57 55 57 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 58 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 59 1
CareDx, Inc 1.2B 61 44 82 50 60 1
IVERIC bio, Inc. 1.1B 84 58 79 70 61 1
FibroGen, Inc. 1.0B 48 74 63 67 62 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 63 1
MannKind Corporation 957.2M 95 48 56 61 64 1
ImmunoGen, Inc. 946.1M 40 73 71 64 65 1
Merus N.V. 941.6M 48 60 59 54 66 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 68 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 69 1
Amarin Corporation plc 734.5M 95 44 82 63 70 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 71 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 72 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 73 1
AnaptysBio, Inc. 586.3M 97 50 77 68 74 1
Geron Corporation 566.2M 89 67 73 78 75 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 76 1
Radius Health, Inc. 499.8M 94 71 68 82 77 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 78 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 79 1
Affimed N.V. 415.0M 95 49 75 66 80 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 81 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 82 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 83 1
Zymeworks Inc. 324.7M 58 53 77 56 84 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 86 1
Silence Therapeutics plc 313.4M 83 64 69 72 87 1
AC Immune SA 299.8M 83 61 65 70 88 1
Precigen, Inc. 299.1M 57 87 59 79 89 1
bluebird bio, Inc. 288.7M 99 91 61 96 90 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 91 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 92 1
MacroGenics, Inc. 184.6M 95 56 74 71 93 1
Chimerix, Inc. 178.4M 99 50 62 65 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Results from Exact Sciences's current financials were concerning, in two areas in particular: Free Cash flow and Asset Turnover. Exact Sciences did a poor job related to generating and maintaining strong free cash flow this period, which stood at -1.9, representing a -37.8% change from the previous filing. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.6%. Their free cash flow situation is more concerning relative to their peers and competitors. Disappointing results in free cash flow often lead to negative pressure in stock prices, so we rated their free cash flow with a score of 45. Also, Exact Sciences's asset turnover metrics were concerning and highlighted potential issues management is having effectively turning assets into sales efficiently. At filing, their asset turnover metrics were 0.3, representing a -8.0% change from the previous period. Companies in the same sector and market capitalization will usually be affected by up to 4.1 percent by this parameter. Their asset turnover numbers are significantly less impressive when compared to their peers and competitors. Therefore, their asset turnover movement earned a score of 46. However, one encouraging metric, Capex, stood out. Exact Sciences's published capital expenditures (CapEx) numbers were encouraging and reflected management's balanced change strategy. Exact Sciences recorded CapEx of -131.5, which represents 3.2% change from the previous report. This remarkable CapEx growth is expected to reinforce upward momentum for its's stock price going forward. The company's CapEx movement, therefore, received a grade of 80. Therefore, it received a cautionary score of 56.

Parameter Value Change Score
Net Cashflow -914.0 22.3% 53
Capital Expenditure -131.5 3.2% 80
Asset Turnover 0.3 -8.0% 46
Free Cashflow -1.9 -37.8% 45
* All values are TTM

The below chart describes Exact Sciences's performance as reflected on its cash flow with respect to its peers. While Exact Sciences received a cash flow score of 56, the average of its peers stands on 69.0.

  •  EXAS
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 0 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 1 1
Vericel Corporation 1.1B 64 46 59 73 65 2 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 3 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 4 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 5 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 6 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 7 1
Immatics N.V. 538.7M 82 95 56 99 86 8 1
Agenus Inc. 520.5M 57 43 52 77 58 9 1
Vaxart, Inc. 440.0M 72 56 53 38 65 10 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 11 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 12 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 13 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 14 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 15 1
DermTech, Inc. 165.3M 60 51 45 86 58 16 1
Amgen Inc. 130.1B 80 74 67 74 81 17 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 18 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 20 1
BioNTech SE 34.0B 73 97 50 52 72 21 1
Seagen Inc. 32.9B 53 53 50 87 58 22 1
Biogen Inc. 29.7B 58 54 90 73 66 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 24 1
Incyte Corporation 16.8B 78 79 92 74 84 25 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 26 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 27 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 28 1
Exelixis, Inc. 6.7B 79 90 89 83 87 29 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 30 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 31 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 32 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 33 1
Alkermes plc 5.0B 89 95 76 80 92 34 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 35 1
Novavax, Inc. 4.0B 62 38 63 54 60 36 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 37 1
Natera, Inc. 3.6B 52 54 56 84 58 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 39 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 40 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 41 1
CureVac N.V. 2.6B 87 80 90 70 90 42 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 43 1
Insmed Incorporated 2.4B 79 80 61 89 82 44 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 45 1
Abgenix Inc. 2.1B 66 53 45 59 58 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 47 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 48 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 50 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 51 1
Xencor, Inc. 1.6B 96 95 70 95 98 52 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 53 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 54 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 55 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 56 1
Veracyte, Inc. 1.4B 90 95 46 46 82 57 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 58 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 59 1
CareDx, Inc 1.2B 98 84 40 50 86 60 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 61 1
FibroGen, Inc. 1.0B 86 74 48 87 84 62 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 63 1
MannKind Corporation 957.2M 77 56 43 37 66 64 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 65 1
Merus N.V. 941.6M 70 71 74 53 71 66 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 68 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 69 1
Amarin Corporation plc 734.5M 52 40 74 55 55 70 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 71 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 72 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 73 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 74 1
Geron Corporation 566.2M 78 68 49 81 77 75 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 76 1
Radius Health, Inc. 499.8M 64 40 37 56 57 77 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 78 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 79 1
Affimed N.V. 415.0M 72 57 95 43 74 80 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 81 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 82 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 83 1
Zymeworks Inc. 324.7M 52 65 45 83 57 84 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 86 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 87 1
AC Immune SA 299.8M 66 77 79 63 68 88 1
Precigen, Inc. 299.1M 82 75 37 85 74 89 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 90 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 91 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 92 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 93 1
Chimerix, Inc. 178.4M 80 84 95 47 83 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.